These data suggested that CSF-1/CSF-1R signaling may be an effective therapeutic target to reprogram the immunosuppressive microenvironment of human PDA tumors and more studies targeting CSF-2/CSF-2R signaling are warranted to enhance the efficacy of pancreatic cancer immunotherapy. The gene discussed is CSF1R; the disease is familial pancreatic carcinoma.